Trastuzumab Deruxtecan Shakes Up HER2-Mutated NSCLC Treatment Paradigm

Solange Peters, MD, discusses the promising clinical activity observed with trastuzumab deruxtecan in patients with HER2-mutated NSCLC, next steps for research, and other exciting lung cancer data.

Read the full article here

Related Articles